Provention could use data from diabetes consortia to bring teplizumab to market faster

Results from a Phase II study showing Provention’s anti-CD3 mAb teplizumab delayed the onset of Type I diabetes in high-risk individuals raised the possibility of a faster path to market than the biotech’s Phase III program in patients with diagnosed disease, and sent its shares skyrocketing up 217% to $13.79 on Monday, translating to $352.7 million in added market cap.

Disease interception play Provention Bio Inc. (NASDAQ:PRVB) launched in 2017 with the goal of

Read the full 748 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE